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Cerebrospinal fluid (CSF) is a potential source of tumor-derived DNA in patients with 
primary or secondary central nervous system (CNS) tumors. Selected mutations in 
CSF circulating tumoral cell-free DNA (cfDNA) have been identified by polymerase 
chain reaction (PCR) detection techniques, and more recently panels of genes have 
been assessed by targeted next-generation sequencing1,2.  
As a matter of fact, different clinically validated platforms for mutational analysis with 
distinct analytical sensitivities are currently available in routine diagnostic practice.  In 
our study we tracked the mutational repertoire in two cases of leptomeningeal 
metastatic disease in synchronous samples of circulating cfDNA derived from plasma 
and CSF using the mass spectrometry technology Sequenom MassARRAY and fast 
COLD-PCR followed by Sanger sequencing. 
In Case 1, a 58 year-old male presenting progressive hearing loss was diagnosed 
with a multifocal moderately differentiated lung adenocarcinoma with a right temporal 
brain metastatic lesion. Following metastasis resection and whole-brain radiation 
therapy, pulmonary lobectomy with lymphadenectomy was performed. Before further 
treatments the patient developed neoplastic meningitis with nodular lumbar 
enhancement on MRI without recurrence at the previous supratentorial metastatic 
site. CSF and plasma samples were obtained from the patient and intrathecal 
chemotherapy with liposomal cytarabine was started. In the following weeks the 
patient’s performance status quickly deteriorated and death occurred seven months 
after the initial diagnosis. 
The patient in Case 2 was a 64 year-old female who presented with headache, 
vertigo and drowsiness. CT and MRI demonstrated a right hemispheric cerebellar 
contrast-enhancing lesion diagnosed after resection as a lung adenocarcinoma 
metastasis. Staging assessments identified a lung neoplasm in the superior left lobe 
associated with mediastinal lymphadenopathies. Following neoadjuvant 
chemotherapy, pulmonary lobectomy with lymphadenectomy was performed, thus 
confirming a poorly differentiated lung adenocarcinoma. After six months, multiple 
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cerebellar metastases developed and were treated with radiotherapy obtaining a 
partial response. Three months later, symptoms suggestive for neoplastic meningitis 
were confirmed by MRI (infratentorial leptomeningeal nodules). Intrathecal 
chemotherapy with liposomal cytarabine was started; however, due to poor patient 
performance this treatment was stopped in favor of palliative care. 
In both cases, DNA was extracted from the tumor resection specimen and from 
synchronous samples of plasma obtained from peripheral blood and of CSF obtained 
from a lumbar puncture performed before starting intrathecal chemotherapy.  
First, we carried out Sequenom using the Lung Status kit, which identifies the main 
nucleotide substitutions affecting EGFR and KRAS in lung adenocarcinoma and 
explores mutations at multiple codons of other relevant genes. The primary tumors of 
Case 1 and Case 2 harbored a p.G13C (c.37G>T, Figure 1A) and a p.G12F 
(c.34_35delGGinsTT, Supplementary Figure 1A) KRAS mutation, respectively. 
These KRAS mutations were absent in plasma but detectable in CSF cfDNA (0.02% 
versus 66.4% for Case 1, Figure 1B-C; 0.02% versus 45% for Case 2, 
Supplementary Figure 1B-C).  
To explore the G>A or G>T KRAS mutations at codons 12/13 with higher analytical 
sensitivity than Sequenom, we then assessed all samples by fast COLD-PCR 
followed by Sanger sequencing. The DNA quantities were all comprised in a range of 
absolute reproducibility to detect a heterozygous mutation3. The p.G13C, as well as 
the p.G12F KRAS mutations identified by Sequenom were detected by fast COLD-
PCR in tissue and in CSF-derived DNA (Figure 1D, 1F; Supplementary Figure 1D, 
1F), while no KRAS mutations were identified in plasma (Figure 1E and 
Supplementary Figure 1E). 
Finally, we measured the extent of DNA fragmentation by calculating a ratio between 
the concentrations of 247/115 bp real-time PCR-amplified products, suggestive of 
apoptosis or necrosis for ratios tending to 1 or 0, respectively4. The ratios observed 
in plasma and CSF samples (51% versus 35% for Case 1 and 100% for both in Case 
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2) indicate a heterogeneous degree of apoptosis in the samples, confirming there is 
no consensus on the origin of the cfDNA (necrosis versus apoptosis)5,6.  
One may argue that we could not detect the KRAS mutation in plasma cfDNA due to 
the analytical sensitivity of our sequencing platform. For KRAS mutations the limit of 
detection estimated for Sequenom is near 5%, provided that a DNA input not below 1 
ng is available. Notably, only the DNA inputs from CSF were below the cutoff (0.8 ng 
for Case 1 and 0.022 ng for Case 2), nevertheless we detected the mutation in these 
samples with a mutant allele frequency much higher than the sensitivity cut off of 5% 
(i.e. 66% for Case 1 and 45% for Case 2). Most importantly, no KRAS mutations 
were identified in plasma cfDNA even when analyzed with a 50-fold more sensitive 
detection method (fast COLD-PCR). 
Our results provide another line of evidence that cfDNA derived from metastatic 
deposits in the brain with clinical features of meningeal carcinomatosis is more 
abundant in CSF compared to plasma. This is a phenomenon likely mediated by the 
intimate contact of CSF with tumor cells and by the compartmentalization of CSF 
from plasma due to the blood-brain barrier. Although accrued only in two patients, 
our data are the first to suggest that the relative enrichment of CSF in tumoral cfDNA 
compared to plasma can reliably allow for comprehensive sequencing of a panel of 
genes by Sequenom MassARRAY in a way akin to targeted panels of massively 
parallel sequencing. In addition, a second-level analysis of specific mutations by fast 
COLD-PCR followed by Sanger sequencing can be employed to guarantee a higher 
enrichment of specific mutant alleles with G>T or G>A substitutions.  
Taken together, these results corroborate the notion that CSF likely represents a 
preferable source of representative liquid biopsy in brain metastatic lesions featuring 
meningeal carcinomatosis, at least when no extra-CNS localizations are evident. 
Liquoral liquid biopsies can help monitor changes in metastatic deposits in the CNS 
and may complement the diagnosis of meningeal carcinomatosis2. Although a lumbar 
puncture is a more invasive procedure than a blood draw, the possible lack of 
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representative tumoral cfDNA in the plasma may delay molecular diagnosis or lead 
to non conclusive results in this delicate subset of patients. Otherwise, liquoral liquid 
biopsy can allow the identification of either actionable genetic alterations or a 
mutation correlated to resistance to targeted therapies leading to crucial changes in 
the treatment decision making. 
In both of the presented cases the detected mutations were not strictly propaedeutic 
to tailor patient treatment (i.e. not actionable): however, in lung cancer patients 
KRAS mutations have been (i) repeatedly implicated as markers of poor prognosis7,8 
and (ii) shown to significantly correlate with brain metastatic disease9. Finally, since 
preclinical evidence suggests the existence of at least two subgroups of mutant 
KRAS lung tumors with distinct genetic/metabolic signatures and unique therapeutic 
susceptibilities assessable on the basis of their relative mutant allelic content10, 
combined quantitative and qualitative KRAS locus assessment may hold both 
prognostic and therapeutic usefulness.  
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FIGURE CAPTIONS 
Figure 1. Detection of DNA alterations in the tumor tissue and in liquid biopsies 
of Case 1. The KRAS mutation c.37G>T, pG13C was diagnosed by Sequenom 
(Myriapod Lung Cancer kit, Diatech Pharmacogenetics, Jesi, Italy) in the tumor 
resection sample (A); the estimated mutant allele frequency was 30% (arrow), 
suggesting a homozygous KRAS mutation since the tumor cell content in the 
selected tumor area accounted for about 30%. The same driver mutation was later 
identified in CSF (C), but not in plasma (B) cfDNA samples. The mutant allele 
frequency of >50% found in the CSF samples (arrow) suggested a likely 
homozygous pattern, in a way akin to the primary tumor. The highly sensitive fast 
COLD-PCR assay detected the same mutation in the tissue sample (D), confirming 
also the negativity of plasma (E) and positivity of CSF (F), using DNA input 
comprised in the range of absolute assay reproducibility3.  
 
Supplementary Figure 1: Detection of DNA alterations in the tumor tissue and 
in liquid biopsies of Case 2. The KRAS mutation c.34_35delGGinsTT, p.G12F,  
was diagnosed by Sequenom in the tumor resection sample (A); the estimated 
mutant allele frequency was 64% (arrow). The same driver mutation was later 
identified in CSF with an estimated mutant allele frequency of 45% (C), but not in 
plasma (B) cfDNA samples. The highly sensitive fast COLD-PCR assay detected the 
same mutation in the tissue sample (D), confirming also the negativity of plasma (E) 
and positivity of CSF (F), using DNA input comprised in the range of absolute assay 
reproducibility3.  
 
 


